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Recent advances in gene editing and therapy have highlighted the potential of ex vivo cell-based techniques to 
treat many diseases, wherein a patient’s cells are harvested, engineered to insert various therapeutic agents 
such as nucleic acids or proteins, and re-infused. Considerable challenges however remain in the ability not just 
to insert these agents into cells whilst retaining high levels of cellular viability, but also to ensure that they are 
not lysed within the cell.  
 
Physical methods (e.g., electroporation, sonoporation, etc.), for example, allow efficient translocation of 
therapeutic cargo into the cell through the formation of pores in the cell membrane. This, however, afflicts some 
damage to the cells, leading to apoptosis of a considerable proportion of the cells. Biochemical methods, in 
contrast, rely on carriers such as nanoparticles, vesicles or viruses to facilitate greater endocytotic take-up. The 
endocytosis pathway nevertheless results in the concentration of the internalised cargo within the endosomal 
regions of the cell, almost all of which ends up in the lysosome where they are degraded, Strategies that allow 
them to escape the endosomal recycling path in order to enter the cytoplasm are therefore required if the cargo 
is to target the nucleus.    
 
We show that exposure of the cells to high frequency (>10 MHz) order sound waves are able to enhance the 
uptake of nanoparticles, molecules and nucleic acids by several-fold, whilst retaining very high levels (>97%) of 
cellular viability. This is because the high frequency excitation, unlike sonoporation, does not result in the 
formation of physical pores in the cell membrane. Instead, the high frequency excitation sufficiently temporarily 
disrupts the structure of the lipids that make up the cell membrane, thus increasing the membrane permeability 
sufficiently to allow the therapeutic agent to diffuse through it. The effect, is however, transient such that the 
organisation of the lipid structure immediately returns to its original state upon relaxation of the acoustic 
excitation. Such immediate recovery of the cell is the reason for the high cell viability. As this internalisation 
mechanism does not involve endocytosis, we observe the therapeutic cargo to be distributed throughout the cell 
instead of being localised within the endosomes or lysosomes (Fig. 1), thus facilitating a greater possibility for 
nuclear targeting and hence transfection. Indeed, with siRNA delivery into human embryonic kidney (HEK293-T) 
cells, we observe a two-fold knockdown in the gene expression 
Figure 1 – Confocal images showing distribution of internalized FITC-labelled gold nanoparticles in 
HEK293-T cells under with and without (control) surface acoustic wave (SAW) excitation.  
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